Another arrow in the NASH quiver?

Affiliations

¹ Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London W2 1NY, UK.
² Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London W2 1NY, UK. Electronic address: p.manousou@imperial.ac.uk.

Comment

Roberta Forlano et al. Lancet Gastroenterol Hepatol. 2023 Feb.

. 2023 Feb;8(2):96-97.

doi: 10.1016/S2468-1253(22)00383-1. Epub 2022 Dec 12.

¹ Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London W2 1NY, UK.
² Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London W2 1NY, UK. Electronic address: p.manousou@imperial.ac.uk.

No abstract available

Conflict of interest statement

We declare no competing interests.

Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study.
Loomba R, Lawitz EJ, Frias JP, Ortiz-Lasanta G, Johansson L, Franey BB, Morrow L, Rosenstock M, Hartsfield CL, Chen CY, Tseng L, Charlton RW, Mansbach H, Margalit M. Loomba R, et al. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):120-132. doi: 10.1016/S2468-1253(22)00347-8. Epub 2022 Dec 12. Lancet Gastroenterol Hepatol. 2023. PMID: 36521501 Clinical Trial.